DK1139743T3 - Exo-S-mecamylaminformulering og anvendelse heraf i behandlinger - Google Patents

Exo-S-mecamylaminformulering og anvendelse heraf i behandlinger

Info

Publication number
DK1139743T3
DK1139743T3 DK99967401T DK99967401T DK1139743T3 DK 1139743 T3 DK1139743 T3 DK 1139743T3 DK 99967401 T DK99967401 T DK 99967401T DK 99967401 T DK99967401 T DK 99967401T DK 1139743 T3 DK1139743 T3 DK 1139743T3
Authority
DK
Denmark
Prior art keywords
exo
mecamylamine
pharmaceutically acceptable
disorder
amount
Prior art date
Application number
DK99967401T
Other languages
Danish (da)
English (en)
Inventor
Douglas Shytle
Paul Sanberg
Mary Newman
Archie Silver
Original Assignee
Univ South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Florida filed Critical Univ South Florida
Application granted granted Critical
Publication of DK1139743T3 publication Critical patent/DK1139743T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
DK99967401T 1998-12-16 1999-12-16 Exo-S-mecamylaminformulering og anvendelse heraf i behandlinger DK1139743T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11253498P 1998-12-16 1998-12-16

Publications (1)

Publication Number Publication Date
DK1139743T3 true DK1139743T3 (da) 2006-07-31

Family

ID=22344414

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05024899T DK1634498T3 (da) 1998-12-16 1999-12-16 Exo-S-mecamylamine formulation
DK99967401T DK1139743T3 (da) 1998-12-16 1999-12-16 Exo-S-mecamylaminformulering og anvendelse heraf i behandlinger

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK05024899T DK1634498T3 (da) 1998-12-16 1999-12-16 Exo-S-mecamylamine formulation

Country Status (12)

Country Link
US (1) US20020016370A1 (ja)
EP (3) EP1139744A4 (ja)
JP (5) JP2002532393A (ja)
AT (2) ATE320711T1 (ja)
AU (2) AU2368600A (ja)
CA (2) CA2393437C (ja)
CY (1) CY1108577T1 (ja)
DE (2) DE69930552T2 (ja)
DK (2) DK1634498T3 (ja)
ES (2) ES2260959T3 (ja)
PT (2) PT1139743E (ja)
WO (2) WO2000035280A1 (ja)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US7045534B2 (en) 2002-02-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of reducing angiogenesis
NO346973B1 (en) 2002-12-20 2023-03-20 Niconovum Ab A physically and chemically stable nicotine-containing particulate material
US20070224284A1 (en) * 2004-03-12 2007-09-27 John Devane Methods and compositions comprising at least one alpha3 beta4 nAChR antagonist or pharmaceutically acceptable salt thereof
EP1603544B1 (en) * 2003-03-14 2007-10-10 AGI Therapeutics Research Limited Treatment of intestinal conditions with n-2,3,3-tetramethylbicyclo 2.2.1 heptan-2-amine
DE10318714B4 (de) * 2003-04-25 2006-03-23 Hf Arzneimittelforschung Gmbh Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches
JP5254616B2 (ja) 2004-09-13 2013-08-07 クロノ セラピューティクス、インコーポレイテッド 生物学的同調性（ｂｉｏｓｙｎｃｈｒｏｎｏｕｓ）経皮的薬物送達
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
AU2006331790A1 (en) * 2005-12-19 2007-07-05 Comentis, Inc. Topical mecamylamine formulations for ocular administration and uses therof
EP1998748B1 (en) 2006-03-16 2015-01-14 NicoNovum AB Improved snuff composition
WO2008045817A2 (en) * 2006-10-09 2008-04-17 Smithkline Beecham Corporation Compositions for reducing nicotine withdrawal symptoms and/or tobacco usage
US20080242947A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Configuring software for effective health monitoring or the like
US20080242951A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Effective low-profile health monitoring or the like
US20080319276A1 (en) * 2007-03-30 2008-12-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
US20090005653A1 (en) * 2007-03-30 2009-01-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
US20080242952A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liablity Corporation Of The State Of Delaware Effective response protocols for health monitoring or the like
US20090018407A1 (en) * 2007-03-30 2009-01-15 Searete Llc, A Limited Corporation Of The State Of Delaware Computational user-health testing
US20080243005A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
US20090119154A1 (en) * 2007-11-07 2009-05-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Determining a demographic characteristic based on computational user-health testing of a user interaction with advertiser-specified content
US20080242949A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
US20090005654A1 (en) * 2007-03-30 2009-01-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational user-health testing
US20080242948A1 (en) * 2007-03-30 2008-10-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Effective low-profile health monitoring or the like
US7718677B2 (en) * 2007-04-02 2010-05-18 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments
WO2009143403A1 (en) * 2008-05-23 2009-11-26 Targacept, Inc. Combination therapy for the management hypertension
AT507187B1 (de) 2008-10-23 2010-03-15 Helmut Dr Buchberger Inhalator
US20120190752A1 (en) * 2009-07-14 2012-07-26 Targacept Inc. Exo-s-mecamylamine method, use, and compound for treatment
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
CN104557568B (zh) * 2010-05-27 2017-04-12 塔加西普特公司 烟碱受体非竞争性拮抗剂
AT510837B1 (de) 2011-07-27 2012-07-15 Helmut Dr Buchberger Inhalatorkomponente
AU2012214085B2 (en) 2011-02-11 2015-07-09 Nicoventures Trading Limited Inhaler component
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
KR102071076B1 (ko) 2011-09-06 2020-03-02 브리티시 아메리칸 토바코 (인베스트먼츠) 리미티드 가열식 끽연 가능 물질
KR102309513B1 (ko) 2011-09-06 2021-10-05 니코벤처스 트레이딩 리미티드 가열식 흡연가능 재료
AT511344B1 (de) 2011-10-21 2012-11-15 Helmut Dr Buchberger Inhalatorkomponente
US8901177B2 (en) * 2012-03-23 2014-12-02 Targacept, Inc. Method of treating bladder disorders
GB201207039D0 (en) 2012-04-23 2012-06-06 British American Tobacco Co Heating smokeable material
GB2504076A (en) 2012-07-16 2014-01-22 Nicoventures Holdings Ltd Electronic smoking device
GB2513637A (en) 2013-05-02 2014-11-05 Nicoventures Holdings Ltd Electronic cigarette
GB2513639A (en) 2013-05-02 2014-11-05 Nicoventures Holdings Ltd Electronic cigarette
GB2514893B (en) 2013-06-04 2017-12-06 Nicoventures Holdings Ltd Container
GB201407426D0 (en) 2014-04-28 2014-06-11 Batmark Ltd Aerosol forming component
GB2528673B (en) 2014-07-25 2020-07-01 Nicoventures Holdings Ltd Aerosol provision system
KR20170040808A (ko) 2014-08-22 2017-04-13 아타카마 세라퓨틱스 인코포레이티드 다한증을 치료하는 방법
GB2533135B (en) 2014-12-11 2020-11-11 Nicoventures Holdings Ltd Aerosol provision systems
EP3250258A4 (en) 2015-01-28 2018-09-05 Chrono Therapeutics, Inc. Drug delivery methods and systems
WO2016145373A1 (en) 2015-03-12 2016-09-15 Chrono Therapeutics Inc. Craving input and support system
GB201511349D0 (en) 2015-06-29 2015-08-12 Nicoventures Holdings Ltd Electronic aerosol provision systems
US11924930B2 (en) 2015-08-31 2024-03-05 Nicoventures Trading Limited Article for use with apparatus for heating smokable material
US20170055584A1 (en) 2015-08-31 2017-03-02 British American Tobacco (Investments) Limited Article for use with apparatus for heating smokable material
CA3103090C (en) 2016-04-27 2023-03-28 Nicoventures Trading Limited Electronic aerosol provision system and vaporizer therefor
AU2018205529B2 (en) 2017-01-06 2023-08-10 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
JP7420797B2 (ja) 2018-05-29 2024-01-23 モーニングサイド ベンチャー インベストメンツ リミテッド 薬剤送達の方法及びシステム
GB202203728D0 (en) * 2022-03-17 2022-05-04 Univ Oxford Innovation Ltd Treatments and methods for increasing dopamine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039801A (en) * 1985-12-20 1991-08-13 The United States Of America As Represented By The Department Of Health & Human Services Thermal fragmentation of methylbenzylurea disastereomers or secondary amines and preparation of optically active secondary amines
US4749686A (en) * 1986-12-04 1988-06-07 New York Medical College Combinations of renal vasodilators and α1 -adrenergic or ganglionic blocking agents and methods for treating diseases
EP0579260A1 (en) * 1987-07-07 1994-01-19 Beecham Group Plc Use of a vasodilator for the treatment of pulmonary hypertension and/or right heart failure-related conditions
US5691365A (en) * 1995-07-18 1997-11-25 University Of Kentucky Research Foundation Nicotinic receptor antagonists in the treatment of neuropharmacological disorders

Also Published As

Publication number Publication date
EP1634498A2 (en) 2006-03-15
EP1634498A3 (en) 2006-03-29
DE69930552T2 (de) 2006-11-30
DE69930552D1 (de) 2006-05-11
AU2368200A (en) 2000-07-03
EP1139743A4 (en) 2003-01-02
WO2000035279A1 (en) 2000-06-22
DK1634498T3 (da) 2008-12-15
JP2011126909A (ja) 2011-06-30
EP1634498B1 (en) 2008-09-03
EP1139743A1 (en) 2001-10-10
ATE406797T1 (de) 2008-09-15
CY1108577T1 (el) 2014-04-09
EP1139744A4 (en) 2003-01-02
AU2368600A (en) 2000-07-03
JP2014051528A (ja) 2014-03-20
ATE320711T1 (de) 2006-04-15
EP1139744A1 (en) 2001-10-10
DE69939498D1 (de) 2008-10-16
ES2260959T3 (es) 2006-11-01
JP2016065108A (ja) 2016-04-28
CA2393437A1 (en) 2000-06-22
WO2000035280A1 (en) 2000-06-22
PT1634498E (pt) 2008-10-28
PT1139743E (pt) 2006-06-30
US20020016370A1 (en) 2002-02-07
CA2393437C (en) 2009-12-15
JP2002532392A (ja) 2002-10-02
EP1139743B1 (en) 2006-03-22
JP2002532393A (ja) 2002-10-02
ES2313187T3 (es) 2009-03-01
CA2393442A1 (en) 2000-06-22

Similar Documents

Publication Publication Date Title
DK1139743T3 (da) Exo-S-mecamylaminformulering og anvendelse heraf i behandlinger
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
TW200607509A (en) Use of optically pure (S,S) -reboxetine in the manufacture of a medicament for the treatment or prevention of chronic fatigue syndrome
WO2002043652A3 (en) Anti-proliferative drugs
BRPI0506881A (pt) derivado de arila diazabicìclica, composição farmacêutica, uso de um derivado de arila diazabicìclica, e, método de tratamento, prevenção ou alìvio de uma doença ou distúrbio ou condição de um corpo de animal vivo
EP1201241A3 (en) Compositions containing capsaicin or capsaicin analogues and a local anesthetic
BR0206559A (pt) Uso de um composto, método de tratamento ou prevenção de disfunções, uso ou método, método de neuroproteção e composto
Summers et al. THA—a review of the literature and its use in treatment of five overdose patients
ATE253039T1 (de) Beta 2 -adrenergische rezeptor-agonisten
NZ522326A (en) Adenosine A2A receptor antagonists
JP2002532392A5 (ja)
WO2004110360A3 (en) Proteoglycan degrading mutants for treatment of cns
Sun et al. Management of tetanus: a review of 18 cases
ES2187646T3 (es) Procedimientos para el tratamiento de inflamaciones y composiciones correspondientes.
Durant et al. Comparison of the neuromuscular blocking properties of Org NC 45 and pancuronium in the rat, cat and rhesus monkey
DE69814089T2 (de) Verwendung von einem draflazin analog zur schmerzbehandlung
BR9708525A (pt) Método de tratamento de insuficência cardíaca com antagonistas de endotelina
Mison-Crighel et al. Glutaminase activity and neocortical excitability
Carlson Supersensitivity to apomorphine and stress two years after chronic methadone treatment
Bakhle et al. Evidence that blood vessels in guinea-pig lung are supplied by both noradrenergic and dopaminergic axons
RU2192275C2 (ru) Способ лечения опийной наркомании
BRPI0409870A (pt) uso de irinotecano para tratamento de cáncer de mama resistente
Kanai et al. Effect of WAL-801, a new antiallergic drug, on chemical mediator-induced bronchoconstrictions in guinea pigs
RU2001132588A (ru) Новое применение вещества для пнс
Middleton Jr et al. Immediate Hypersensitivity: II. Drugs in Clinical Use